Indication

As monotherapy or in combination with platinum and 5-fluorouracil (5-FU) chemotherapy, is indicated for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD-L1 with a CPS ≥ 1.

Medicine details

Medicine name:
pembrolizumab (Keytruda)
SMC ID:
SMC2257
Pharmaceutical company
Merck Sharp & Dohme Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
Q2 2020
SMC meeting date:
Q2 2020
Patient group submission deadline:
02 March 2020